Alemtuzumab
Links shared publicly online about this topic
Oncology Medical News about Alemtuzumab
mdlinx.com — “Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective” View full resource at mdlinx.com
Most Recently Shared on April 19, 2010 at 9:05 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective: Bone Marrow Transpl... http://bit.ly/cKrfUT #oncology
Genzyme Details Market Potential Of Alemtuzumab For MS
medicalnewstoday.com — “Genzyme Corporation (NASDAQ: GENZ) provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York. During the two-h” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 6:05 pm By:
Genzyme Details Market Potential Of Alemtuzumab For MS http://mnt.to/3PYs #multiplesclerosis
Genzyme Details Market Potential of Alemtuzumab for MS
businesswire.com — “Press Release Content” View full resource at businesswire.com
Most Recently Shared on December 20, 2010 at 7:54 pm By:
Genzyme Details Market Potential of Alemtuzumab for MS http://bit.ly/gOzvjE
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
neurology.org — “Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort” View full resource at neurology.org
Most Recently Shared on August 12, 2011 at 2:02 pm By:
Neurology Journal Medical Journal and Neurology
Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort http://bit.ly/qp98cM
Fast track designation granted for alemtuzumab for multiple sclerosis (MS) - ONA
oncologynurseadvisor.com — “Genzyme announced that the FDA has granted fast track designation to alemtuzumab for the treatment of multiple sclerosis (MS).” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 15, 2010 at 4:08 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Fast track designation granted for alemtuzumab for multiple sclerosis (MS) http://goo.gl/fb/zMrWT
Fast track designation granted for alemtuzumab for multiple sclerosis (MS) - MPR
empr.com — “Genzyme announced that the FDA has granted fast track designation to alemtuzumab for the treatment of multiple sclerosis (MS).” View full resource at empr.com
Most Recently Shared on June 15, 2010 at 4:45 pm By:
MPR News: Fast track designation granted for alemtuzumab for multiple sclerosis (MS): Genzyme announced that the F... http://bit.ly/dd4yxx
Alemtuzumab Raises CMV Infection Risk - Renal and Urology News
renalandurologynews.com — “VANCOUVER"Cytomegalovirus (CMV) infection in kidney or kidney/pancreas transplant recipients occurs more frequently when alemtuzumab is used for induction instead of antithymocyte globulin (ATG), according to a new study from the University of Minnesota in Minneapolis.” View full resource at renalandurologynews.com
Most Recently Shared on October 26, 2010 at 3:38 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Alemtuzumab Raises CMV Infection Risk: VANCOUVER—Cytomegalovirus (CMV) infection in kidney or kidney/pancreas tran... http://bit.ly/b8asI5
Alemtuzumab Reduces Minimal Residual Disease in CLL Patients : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on January 6, 2011 at 6:32 pm By:
Bob Finn - Medical News Net Health News
Alemtuzumab eliminates residual disease in 83% of patients w chronic lymphocytic leukemia. @hsplete reports. http://bit.ly/hHAsjN
Five Year Follow-Up Data Show Alemtuzumab Achieves Sustained Reduction In Relapses And Disability In Multiple Sclerosis
medicalnewstoday.com — “Patients with multiple sclerosis (MS) treated with alemtuzumab show sustained reduction in relapses and disability after five years, according to results reported at the European Committee for Tre” View full resource at medicalnewstoday.com
Most Recently Shared on October 15, 2010 at 4:06 pm By:
Five Year Follow-Up Data Show Alemtuzumab Achieves Sustained Reduction In Relapses And Disability In Multiple Sclerosis http://mnt.to/3LgB
Fludarabine, alemtuzumab extended PFS by 7 months in CLL | HemOncToday
hemonctoday.com — “Fludarabine combined with alemtuzumab improved PFS for patients with chronic lymphocytic leukemia compared with fludarabine alone, according to” View full resource at hemonctoday.com
Most Recently Shared on October 12, 2011 at 8:36 pm By:
HemOnc Today Oncology and Health News
#Fludarabine, #alemtuzumab extended PFS by 7 months in CLL http://t.co/7rqW7TQK
GSK and Genmab announce topline results from the concluded pivotal trial of Arzerra (ofatumumab) in fludarabine and alemtuzumab refractory chronic lymphocytic leukemia
gsk.com — “GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today top line results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).” View full resource at gsk.com
Most Recently Shared on August 9, 2010 at 9:10 pm By:
eyeonfda Pharma and Health Lawyer
GSK & Genmab - resultsof pivotal trial Arzerra (ofatumumab) in fludarabine & alemtuzumab refr chron lymphocytic leukemia http://ow.ly/2ncoe
ECTRIMS: Early Alemtuzumab Still Works at Five Years (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- GOTHENBURG, Sweden -- Two annual treatments with alemtuzumab remain effective for at least five years in preventing disability progression in MS, though safety concerns remain.” View full resource at qualitypointtech.net
Most Recently Shared on October 15, 2010 at 8:49 pm By:
ECTRIMS: Early Alemtuzumab Still Works at Five Years (CME/CE): (MedPage Today) -- GOTHENBURG, Sweden -- Two annual... http://bit.ly/9skTgo
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS
news-medical.net — “Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.” View full resource at news-medical.net
Most Recently Shared on June 15, 2010 at 6:12 am By:
FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS: Genzyme Corporation announced t... http://bit.ly/a2yIsx
Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting
news-medical.net — “Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.” View full resource at news-medical.net
Most Recently Shared on April 8, 2011 at 5:46 am By:
Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting: Genzyme, a subsidiary of sanofi-a... http://bit.ly/esQJ2s
Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS
news-medical.net — “Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.” View full resource at news-medical.net
Most Recently Shared on April 15, 2011 at 9:51 am By:
Genzyme reports positive data from 5-year alemtuzumab Phase 2 study in MS: Genzyme Corp., a subsidiary of sanofi... http://bit.ly/f0aQFV
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MNT Multiple Scl
The latest multiple sclerosis news published daily. Articles from research centers, universities and prestigious journals.
-
Genzyme Corporation
The official Twitter site of Genzyme Corporation.
Advertisement
